Dr Jacob Peedicayil completed MBBS in 1984 and MD in pharmacology in 1991, both at the Christian Medical College, Vellore, India. From 1993 to 1995 he did a Post-Doctoral Fellowship at the Centre for Cellular and Molecular Biology, Hyderabad, India. From 1995 to 1998 he worked as a Research Fellow in the Department of Neurological Sciences, Christian Medical College, Vellore. Since 1998 he has been on the faculty of the Department of Pharmacology and Clinical Pharmacology, Christian Medical College, Vellore, becoming a professor in 2007. He does theoretical research on epigenetics, focusing on epigenetics in psychiatry. In addition, he is involved in experimental research in smooth muscle pharmacology. Dr Dennis R. Grayson received his PhD from the Department of Biochemistry at Wayne State University School of Medicine in 1984. He has been interested in mechanisms associated with gene expression for over 35 years. He joined the laboratory of Dr James E. Darnell at the Rockefeller University as a Post-Doctoral Fellow in 1984 to study cell-type specific transcription factors and their interaction with promoters and enhancers. In 1988, Dr Grayson joined the Fidia-Georgetown Institute for the Neurosciences at Georgetown University to study gene expression programs in neurons and continued this research program at Allegheny Singer Research Institutein Pittsburgh from 1995 to 1998. He continued his interests in psychiatry and joined the Psychiatric Institute at the University of Illinois in 1998. This represented a unique opportunity to pursue the molecular underpinnings of schizophrenia. Dr Grayson has received NRSA post-doctoral support, and R01 and K04 funding from the National Institutes of Health to support his work. He has published over 140 papers in peer-reviewed journals and is regularly invited to speak at numerous national and international meetings. He is currently Director of the Epigenetic Core of the Center for Alcohol Research in Epigenetics.

• Section I. Neuropsychiatric Disorders and Epigenetics: General Aspects1. Introduction to Neuropsychiatric Disorders and Epigenetics2. Environmental Factors and Epigenetics of Neuropsychiatric Disorders3. Epigenetic Biomarkers in Neuropsychiatric Disorders4. Epigenetics and Neuroimaging in Neuropsychiatric Disorders5. Recent advances in genome-wide approaches to biomedical research6. Single Cell Epigenomic Approaches in Neuropsychiatric Disorders7. Neuropsychiatric Disorders and Epigenetics: Computational Approaches; Sampling methods; and Power analysesSection II: Epigenetics of Neuropsychiatric Disorders 8. Epigenetics and Cognitive Disorders -Translational Aspects9. Epigenetics in Autism Spectrum Disorders - Translational Aspects10. Epigenetic causes of intellectual disability – the fragile X syndrome paradigm11. Epigenetics of Attention-Deficit Hyperactivity Disorder12. The epigenetics of brain aging and psychiatric disorders13. Epigenetic therapy may alleviate cognitive deficits in Down syndrome by downregulating overexpressed chromosome 21 gene products14. Epigenetics and Multiple Sclerosis15. Epigenetics and Migraine16. The role of epigenetics in the pathophysiology of epilepsy17. Epigenetic Dysregulation in Brain Tumors and Neurodevelopment18. Epigenetics and Cerebrovascular Diseases19. Epigenetics of Spinal Muscular Atrophy and the Potential Role of Epigenetics in the Treatment of this Disorder20. Epigenetics and Anxiety Disorders21. Epigenetics and Eating Disorders22. Epigenetics in Obesity23. Epigenetics and Drug Addiction-Translational Aspects24. Epigenetics and Alcohol Use DisordersSection III: Summary and Outlook25. Summary and Outlook

Dr Jacob Peedicayil completed MBBS in 1984 and MD in pharmacology in 1991, both at the Christian Medical College, Vellore, India. From 1993 to 1995 he did a Post-Doctoral Fellowship at the Centre for Cellular and Molecular Biology, Hyderabad, India. From 1995 to 1998 he worked as a Research Fellow in the Department of Neurological Sciences, Christian Medical College, Vellore. Since 1998 he has been on the faculty of the Department of Pharmacology and Clinical Pharmacology, Christian Medical College, Vellore, becoming a professor in 2007. He does theoretical research on epigenetics, focusing on epigenetics in psychiatry. In addition, he is involved in experimental research in smooth muscle pharmacology. Dr Dennis R. Grayson received his PhD from the Department of Biochemistry at Wayne State University School of Medicine in 1984. He has been interested in mechanisms associated with gene expression for over 35 years. He joined the laboratory of Dr James E. Darnell at the Rockefeller University as a Post-Doctoral Fellow in 1984 to study cell-type specific transcription factors and their interaction with promoters and enhancers. In 1988, Dr Grayson joined the Fidia-Georgetown Institute for the Neurosciences at Georgetown University to study gene expression programs in neurons and continued this research program at Allegheny Singer Research Institutein Pittsburgh from 1995 to 1998. He continued his interests in psychiatry and joined the Psychiatric Institute at the University of Illinois in 1998. This represented a unique opportunity to pursue the molecular underpinnings of schizophrenia. Dr Grayson has received NRSA post-doctoral support, and R01 and K04 funding from the National Institutes of Health to support his work. He has published over 140 papers in peer-reviewed journals and is regularly invited to speak at numerous national and international meetings. He is currently Director of the Epigenetic Core of the Center for Alcohol Research in Epigenetics.

• Section I. Neuropsychiatric Disorders and Epigenetics: General Aspects1. Introduction to Neuropsychiatric Disorders and Epigenetics2. Environmental Factors and Epigenetics of Neuropsychiatric Disorders3. Epigenetic Biomarkers in Neuropsychiatric Disorders4. Epigenetics and Neuroimaging in Neuropsychiatric Disorders5. Recent advances in genome-wide approaches to biomedical research6. Single Cell Epigenomic Approaches in Neuropsychiatric Disorders7. Neuropsychiatric Disorders and Epigenetics: Computational Approaches; Sampling methods; and Power analysesSection II: Epigenetics of Neuropsychiatric Disorders 8. Epigenetics and Cognitive Disorders -Translational Aspects9. Epigenetics in Autism Spectrum Disorders - Translational Aspects10. Epigenetic causes of intellectual disability – the fragile X syndrome paradigm11. Epigenetics of Attention-Deficit Hyperactivity Disorder12. The epigenetics of brain aging and psychiatric disorders13. Epigenetic therapy may alleviate cognitive deficits in Down syndrome by downregulating overexpressed chromosome 21 gene products14. Epigenetics and Multiple Sclerosis15. Epigenetics and Migraine16. The role of epigenetics in the pathophysiology of epilepsy17. Epigenetic Dysregulation in Brain Tumors and Neurodevelopment18. Epigenetics and Cerebrovascular Diseases19. Epigenetics of Spinal Muscular Atrophy and the Potential Role of Epigenetics in the Treatment of this Disorder20. Epigenetics and Anxiety Disorders21. Epigenetics and Eating Disorders22. Epigenetics in Obesity23. Epigenetics and Drug Addiction-Translational Aspects24. Epigenetics and Alcohol Use DisordersSection III: Summary and Outlook25. Summary and Outlook

Dr Jacob Peedicayil completed MBBS in 1984 and MD in pharmacology in 1991, both at the Christian Medical College, Vellore, India. From 1993 to 1995 he did a Post-Doctoral Fellowship at the Centre for Cellular and Molecular Biology, Hyderabad, India. From 1995 to 1998 he worked as a Research Fellow in the Department of Neurological Sciences, Christian Medical College, Vellore. Since 1998 he has been on the faculty of the Department of Pharmacology and Clinical Pharmacology, Christian Medical College, Vellore, becoming a professor in 2007. He does theoretical research on epigenetics, focusing on epigenetics in psychiatry. In addition, he is involved in experimental research in smooth muscle pharmacology. Dr Dennis R. Grayson received his PhD from the Department of Biochemistry at Wayne State University School of Medicine in 1984. He has been interested in mechanisms associated with gene expression for over 35 years. He joined the laboratory of Dr James E. Darnell at the Rockefeller University as a Post-Doctoral Fellow in 1984 to study cell-type specific transcription factors and their interaction with promoters and enhancers. In 1988, Dr Grayson joined the Fidia-Georgetown Institute for the Neurosciences at Georgetown University to study gene expression programs in neurons and continued this research program at Allegheny Singer Research Institutein Pittsburgh from 1995 to 1998. He continued his interests in psychiatry and joined the Psychiatric Institute at the University of Illinois in 1998. This represented a unique opportunity to pursue the molecular underpinnings of schizophrenia. Dr Grayson has received NRSA post-doctoral support, and R01 and K04 funding from the National Institutes of Health to support his work. He has published over 140 papers in peer-reviewed journals and is regularly invited to speak at numerous national and international meetings. He is currently Director of the Epigenetic Core of the Center for Alcohol Research in Epigenetics.

• Section I. Neuropsychiatric Disorders and Epigenetics: General Aspects1. Introduction to Neuropsychiatric Disorders and Epigenetics2. Environmental Factors and Epigenetics of Neuropsychiatric Disorders3. Epigenetic Biomarkers in Neuropsychiatric Disorders4. Epigenetics and Neuroimaging in Neuropsychiatric Disorders5. Recent advances in genome-wide approaches to biomedical research6. Single Cell Epigenomic Approaches in Neuropsychiatric Disorders7. Neuropsychiatric Disorders and Epigenetics: Computational Approaches; Sampling methods; and Power analysesSection II: Epigenetics of Neuropsychiatric Disorders 8. Epigenetics and Cognitive Disorders -Translational Aspects9. Epigenetics in Autism Spectrum Disorders - Translational Aspects10. Epigenetic causes of intellectual disability – the fragile X syndrome paradigm11. Epigenetics of Attention-Deficit Hyperactivity Disorder12. The epigenetics of brain aging and psychiatric disorders13. Epigenetic therapy may alleviate cognitive deficits in Down syndrome by downregulating overexpressed chromosome 21 gene products14. Epigenetics and Multiple Sclerosis15. Epigenetics and Migraine16. The role of epigenetics in the pathophysiology of epilepsy17. Epigenetic Dysregulation in Brain Tumors and Neurodevelopment18. Epigenetics and Cerebrovascular Diseases19. Epigenetics of Spinal Muscular Atrophy and the Potential Role of Epigenetics in the Treatment of this Disorder20. Epigenetics and Anxiety Disorders21. Epigenetics and Eating Disorders22. Epigenetics in Obesity23. Epigenetics and Drug Addiction-Translational Aspects24. Epigenetics and Alcohol Use DisordersSection III: Summary and Outlook25. Summary and Outlook